C

China Meheco Group Co Ltd
SSE:600056

Watchlist Manager
China Meheco Group Co Ltd
SSE:600056
Watchlist
Price: 10.83 CNY -0.37%
Market Cap: ¥16.2B

Net Margin

1.6%
Current
Declining
by 0.3%
vs 3-y average of 1.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
1.6%
=
Net Income
¥543.1m
/
Revenue
¥33.9B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
1.6%
=
Net Income
¥543.1m
/
Revenue
¥33.9B

Peer Comparison

Country Company Market Cap Net
Margin
CN
China Meheco Group Co Ltd
SSE:600056
16.2B CNY
Loading...
JP
Mitsubishi Corp
TSE:8058
17.4T JPY
Loading...
JP
Itochu Corp
TSE:8001
15.8T JPY
Loading...
JP
Mitsui & Co Ltd
TSE:8031
14.7T JPY
Loading...
JP
Marubeni Corp
TSE:8002
8.9T JPY
Loading...
US
W W Grainger Inc
NYSE:GWW
56.9B USD
Loading...
US
WW Grainger Inc
XMUN:GWW
47.9B EUR
Loading...
US
Fastenal Co
NASDAQ:FAST
54.3B USD
Loading...
US
United Rentals Inc
NYSE:URI
53.1B USD
Loading...
US
Ferguson Enterprises Inc
NYSE:FERG
50B USD
Loading...
JP
Sumitomo Corp
TSE:8053
7.2T JPY
Loading...

Market Distribution

In line with most companies in China
Percentile
41st
Based on 8 721 companies
41st percentile
1.6%
Low
-416 945.9% — -1.5%
Typical Range
-1.5% — 8.9%
High
8.9% — 17 382.1%
Distribution Statistics
China
Min -416 945.9%
30th Percentile -1.5%
Median 3.5%
70th Percentile 8.9%
Max 17 382.1%

China Meheco Group Co Ltd
Glance View

China Meheco Group Co., Ltd., established in 1984, stands as a prominent player in the Chinese pharmaceutical and healthcare sector. As the company evolved over the decades, it navigated the complex Chinese market by strategically positioning itself across the entire pharmaceutical value chain. This involved investing heavily in research and development, securing partnerships with both domestic and international pharmaceutical companies, and streamlining its distribution network to enhance efficiency. Such endeavors have enabled China Meheco to develop and distribute a wide range of medical products, including active pharmaceutical ingredients, finished drugs, medical devices, and traditional Chinese medicines. The company leverages its robust R&D capabilities to continually bring innovative products to market, which has been a significant source of its revenue. China Meheco's business model thrives on its expansive distribution network and strategic collaborations. By aligning with global pharmaceutical giants, the company not only gains access to cutting-edge technologies and advanced formulations but also expands its market reach beyond China. This dual strategy of innovation and partnership ensures a steady flow of products that cater to diverse healthcare needs. Furthermore, China Meheco capitalizes on its local expertise and deep understanding of regulatory frameworks, allowing it to maneuver efficiently within China's complex healthcare landscape. This approach underpins its ability to capture substantial market share in a competitive industry, driving profitability and positioning the company as a key player in the global pharmaceutical arena.

Intrinsic Value
15.06 CNY
Undervaluation 28%
Intrinsic Value
Price
C
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
1.6%
=
Net Income
¥543.1m
/
Revenue
¥33.9B
What is China Meheco Group Co Ltd's current Net Margin?

The current Net Margin for China Meheco Group Co Ltd is 1.6%, which is below its 3-year median of 1.9%.

How has Net Margin changed over time?

Over the last 3 years, China Meheco Group Co Ltd’s Net Margin has increased from 1.6% to 1.6%. During this period, it reached a low of 1.4% on Sep 30, 2023 and a high of 2.7% on Dec 31, 2023.

Back to Top